摘要
目的 探讨钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂辅助治疗急性冠状动脉综合征(ACS)的临床疗效。方法 选取医院2020年8月至2021年8月收治的ACS患者120例,按随机数字表法分为观察组和对照组,各60例。两组患者均予常规治疗,观察组患者加用SGLT2抑制剂恩格列净或达格列净,均连续治疗12个月。结果 观察组总有效率为91.67%,显著高于对照组的78.33%(P <0.05)。治疗1个月、6个月后,两组患者的心功能指标左室舒张末期容积、左室收缩末期容积均显著降低(P <0.05),左室射血分数显著升高(P <0.05),且观察组上述指标改善程度均显著优于对照组(P <0.05);两组患者的炎性因子超敏C反应蛋白、白细胞介素6、肿瘤坏死因子-α水平均显著降低(P <0.05),且观察组均显著低于对照组(P <0.05);观察组患者的左室重构指标可溶性生长刺激表达基因2蛋白、Ⅰ型前胶原羧基端肽、Ⅰ型C端胶原前肽均显著低于对照组(P <0.05)。治疗1个月后,两组患者的心肌酶谱乳酸脱氢酶、肌酸激酶同工酶、肌酸激酶水平均显著降低(P <0.05),且观察组均显著低于对照组(P <0.05)。观察组患者的主要心血管不良事件(MACE)发生率为6.67%,显著低于对照组的20.00%(P <0.05)。结论 SGLT2抑制剂辅助治疗ACS的临床疗效良好,可有效改善患者的心功能,减轻心肌损伤及机体炎症,逆转心室重构,降低MACE发生率。
Objective To investigate the clinical efficacy of sodium-glucose cotransporter 2(SGLT-2) inhibitors in theadjuvant treatment of acute coronary syndrome(ACS).Methods A total of 120 patients with ACS admitted to the Qinzhou FirstPeople′s Hospital from August 2020 to August 2021 were selected and divided into the observation group and the control groupaccording to the random number table method,with 60 cases in each group.The patients in the two groups received routinetreatment,on this basis,the patients in the observation group received SGLT2 inhibitors such as empagliflozin or dapagliflozin.Bothgroups were continuously treated for 12 months.Results The total effective rate in the observation group was 91.67%,which wassignificantly higher than 78.33% in the control group(P < 0.05).After one and six months of treatment,the cardiac functionindexes [left ventricular end-diastolic volume(LVEDV) and left ventricular end-systolic volume(LVESV)] in the two groupssignificantly decreased(P < 0.05),while the left ventricular ejection fraction(LVEF) in the two groups significantly increased(P < 0.05),and the improvement of the above indexes in the observation group was significantly better than that in the controlgroup(P < 0.05).The levels of inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6),and tumor necrosis factor-α(TNF-α)] in the two groups significantly decreased(P < 0.05),and those in the observationgroup were significantly lower than those in the control group(P < 0.05).The left ventricular remodeling indexes [soluble growthstimulation gene 2 protein(s ST2),type Ⅰ procollagen carboxy-terminal peptide(PⅠCP),typeⅠC-terminal collagen propeptide(CⅠTP)] in the observation group were significantly lower than those in the control group(P < 0.05).After one month oftreatment,the levels of myocardial enzyme profiles [lactate dehydrogenase(LDH),creatine kinase isozyme(CK-MB),creatinekinase(CK)] in the two groups significantly decreased(P < 0.05),and those in the observation group wer
作者
李家海
石林
曾凡鹏
吴杨武
LI Jiahai;SHI Lin;ZENG Fanpeng;WU Yangwu(Qinzhou First People′s Hospital,Qinzhou,Guangxi,China 535000)
出处
《中国药业》
CAS
2024年第15期87-91,共5页
China Pharmaceuticals
基金
广西壮族自治区钦州市科学研究与技术开发计划项目[20202714]。
